Does tesamorelin burn fat?

It reduced visceral fat in the population it was approved for. In people with HIV-associated lipodystrophy, 412 people at 26 weeks saw visceral fat down 15.2% versus a 5.0% rise on placebo, and 806 pooled across both Phase 3 trials showed a treatment effect of minus 15.4% VAT with no change in subcutaneous fat. A 61-person trial in HIV and fatty liver found hepatic fat fraction fell further on tesamorelin, absolute effect minus 4.1 percent. Those are visceral-fat and liver-fat results in HIV cohorts, not a general burns-fat finding in people without that diagnosis, and they are not a subcutaneous-fat result. A research-chemical vial labeled tesamorelin is not Egrifta. This FAQ does not move those VAT numbers onto a general weight-loss claim. Full record at /compounds/tesamorelin.

Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.

Part of growth hormone secretagogues. Sermorelin, tesamorelin, ipamorelin, CJC-1295, and the rest of the GHRH and ghrelin receptor family.